Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with RocheGlobeNewsWire • 02/26/24
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory BoardGlobeNewsWire • 02/20/24
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28GlobeNewsWire • 02/14/24
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key MilestonesGlobeNewsWire • 02/13/24
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General MeetingGlobeNewsWire • 02/01/24
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA PolymeraseGlobeNewsWire • 12/13/23
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ PlatformGlobeNewsWire • 12/13/23
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics ManufacturingGlobeNewsWire • 12/11/23
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023GlobeNewsWire • 11/28/23
Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility LeaseGlobeNewsWire • 09/07/23
Cathie Wood's ARK Funds Continue to Buy These 5 Stellar ‘Strong Buy' Stocks Trading Under $1024/7 Wall Street • 08/05/23